9/18/2013 6:51:11 AM
Aerie Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
BEDMINSTER, N.J & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc., announced today that the Company has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to Aerie’s proposed initial public offering.
The offering will consist of common stock of Aerie. The number of shares to be offered and the price range for the offering have not been determined. A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. Aerie plans to list its common stock on the NASDAQ Global Market under the ticker symbol “AERI.”
RBC Capital Markets and Stifel will serve as joint book-running managers for the offering. Lazard Capital Markets and Canaccord Genuity will serve as co-managers.
This offering will be made only by means of a prospectus. A copy of the preliminary prospectus, when available, can be obtained from RBC Capital Markets, LLC, Attention: Equity Syndicate, Three World Financial Center, 200 Vesey Street, 8th Floor, New York, New York 10281, or by telephone at (877) 822-4089, or from Stifel, Nicolaus & Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by telephone at (415) 364-2720.
This news release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.
Aerie’s lead product candidate, AR-13324, is the first of a new dual-action drug class that was discovered by Aerie scientists. AR-13324 is a once-daily eye drop designed to reduce intraocular pressure in patients with glaucoma or ocular hypertension. Aerie’s product candidate PG324 is a fixed combination of dual-action AR-13324 with latanoprost formulated in a single eye drop and is designed to lower intraocular pressure by reducing fluid inflow while also opening both of the eye’s fluid drains.
Aerie is located in Bedminster, New Jersey, Research Triangle Park, North Carolina, and Newport Beach, California.
Richard Rubino, 908-470-4320
Burns McClellan, Inc., on behalf of Aerie Pharmaceuticals
Justin Jackson, 212-213-0006
Help employers find you! Check out all the jobs and post your resume.